Rahman Shah1, Samuel B Latham1, Sajjad A Khan2, Muhammad Shahreyar1, Inyong Hwang1, Ion S Jovin3. 1. Department of Internal Medicine, University of Tennessee, Memphis, Tennessee. 2. Department of Internal Medicine, Aga Khan University, Karachi, Pakistan. 3. Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia.
Abstract
BACKGROUND: A substantial proportion of patients with coronary artery disease do not achieve complete revascularization and continue to experience refractory angina despite optimal medical therapy. Recently, stem cell therapy has emerged as a potential therapeutic option for these patients. However, findings of individual trials have been scrutinized because of their small sample sizes and lack of statistical power. Therefore, we conducted an updated comprehensive meta-analysis of available randomized controlled trials (RCTs) with the largest sample size ever reported on this subject. HYPOTHESIS: In patients with chronic angina stem cell therapy improves clinical outcomes. METHODS: Scientific databases and websites were searched for RCTs. Data were independently collected by 2 investigators, and disagreements were resolved by consensus. Data from 10 trials including 658 patients were analyzed. RESULTS: Stem cell therapy improved Canadian Cardiovascular Society angina class (risk ratio: 1.53, 95% CI: 1.09 to 2.15, P = 0.013), exercise capacity (standardized mean difference [SMD]: 0.56, 95% CI: 0.23 to 0.88, P = 0.001), and left ventricular ejection fraction (SMD: 0.63, 95% CI: 0.27 to 1.00, P = 0.001) compared with placebo. It also decreased anginal episodes (SMD: -1.21, 95% CI: -2.40 to -0.02, P = 0.045) and myocardial perfusion defects (SMD: -0.70, 95% CI: -1.11 to -0.29, P = 0.001). However, no improvements in all-cause mortality were observed after a relatively short follow-up. CONCLUSIONS: In patients with chronic angina on optimal medical therapy, stem cell therapy improves symptoms, exercise capacity, and left ventricular ejection fraction. These findings warrant confirmation using larger trials.
BACKGROUND: A substantial proportion of patients with coronary artery disease do not achieve complete revascularization and continue to experience refractory angina despite optimal medical therapy. Recently, stem cell therapy has emerged as a potential therapeutic option for these patients. However, findings of individual trials have been scrutinized because of their small sample sizes and lack of statistical power. Therefore, we conducted an updated comprehensive meta-analysis of available randomized controlled trials (RCTs) with the largest sample size ever reported on this subject. HYPOTHESIS: In patients with chronic angina stem cell therapy improves clinical outcomes. METHODS: Scientific databases and websites were searched for RCTs. Data were independently collected by 2 investigators, and disagreements were resolved by consensus. Data from 10 trials including 658 patients were analyzed. RESULTS: Stem cell therapy improved Canadian Cardiovascular Society angina class (risk ratio: 1.53, 95% CI: 1.09 to 2.15, P = 0.013), exercise capacity (standardized mean difference [SMD]: 0.56, 95% CI: 0.23 to 0.88, P = 0.001), and left ventricular ejection fraction (SMD: 0.63, 95% CI: 0.27 to 1.00, P = 0.001) compared with placebo. It also decreased anginal episodes (SMD: -1.21, 95% CI: -2.40 to -0.02, P = 0.045) and myocardial perfusion defects (SMD: -0.70, 95% CI: -1.11 to -0.29, P = 0.001). However, no improvements in all-cause mortality were observed after a relatively short follow-up. CONCLUSIONS: In patients with chronic angina on optimal medical therapy, stem cell therapy improves symptoms, exercise capacity, and left ventricular ejection fraction. These findings warrant confirmation using larger trials.
Authors: Rahman Shah; Samuel B Latham; Sajjad A Khan; Muhammad Shahreyar; Inyong Hwang; Ion S Jovin Journal: Clin Cardiol Date: 2018-04-17 Impact factor: 2.882
Authors: Mariann Gyöngyösi; Wojciech Wojakowski; Patricia Lemarchand; Ketil Lunde; Michal Tendera; Jozef Bartunek; Eduardo Marban; Birgit Assmus; Timothy D Henry; Jay H Traverse; Lemuel A Moyé; Daniel Sürder; Roberto Corti; Heikki Huikuri; Johanna Miettinen; Jochen Wöhrle; Slobodan Obradovic; Jérome Roncalli; Konstantinos Malliaras; Evgeny Pokushalov; Alexander Romanov; Jens Kastrup; Martin W Bergmann; Douwe E Atsma; Axel Diederichsen; Istvan Edes; Imre Benedek; Theodora Benedek; Hristo Pejkov; Noemi Nyolczas; Noemi Pavo; Jutta Bergler-Klein; Imre J Pavo; Christer Sylven; Sergio Berti; Eliano P Navarese; Gerald Maurer Journal: Circ Res Date: 2015-02-19 Impact factor: 17.367
Authors: Jan van Ramshorst; Jeroen J Bax; Saskia L M A Beeres; Petra Dibbets-Schneider; Stijntje D Roes; Marcel P M Stokkel; Albert de Roos; Willem E Fibbe; Jaap J Zwaginga; Eric Boersma; Martin J Schalij; Douwe E Atsma Journal: JAMA Date: 2009-05-20 Impact factor: 56.272
Authors: Douglas W Losordo; Richard A Schatz; Christopher J White; James E Udelson; Vimal Veereshwarayya; Michelle Durgin; Kian Keong Poh; Robert Weinstein; Marianne Kearney; Muqtada Chaudhry; Aaron Burg; Liz Eaton; Lindsay Heyd; Tina Thorne; Leon Shturman; Peter Hoffmeister; Ken Story; Victor Zak; Douglas Dowling; Jay H Traverse; Rachel E Olson; Janice Flanagan; Donata Sodano; Toshinori Murayama; Atsuhiko Kawamoto; Kengo Fukushima Kusano; Jill Wollins; Frederick Welt; Pinak Shah; Peter Soukas; Takayuki Asahara; Timothy D Henry Journal: Circulation Date: 2007-06-11 Impact factor: 29.690
Authors: Timothy D Henry; Carl J Pepine; Charles R Lambert; Jay H Traverse; Richard Schatz; Marco Costa; Thomas J Povsic; R David Anderson; James T Willerson; Steven Kesten; Emerson C Perin Journal: Catheter Cardiovasc Interv Date: 2016-09-23 Impact factor: 2.692
Authors: Julian P T Higgins; Douglas G Altman; Peter C Gøtzsche; Peter Jüni; David Moher; Andrew D Oxman; Jelena Savovic; Kenneth F Schulz; Laura Weeks; Jonathan A C Sterne Journal: BMJ Date: 2011-10-18
Authors: David Moher; Larissa Shamseer; Mike Clarke; Davina Ghersi; Alessandro Liberati; Mark Petticrew; Paul Shekelle; Lesley A Stewart Journal: Syst Rev Date: 2015-01-01
Authors: Rahman Shah; Samuel B Latham; Sajjad A Khan; Muhammad Shahreyar; Inyong Hwang; Ion S Jovin Journal: Clin Cardiol Date: 2018-04-17 Impact factor: 2.882